NASDAQ:XBIT XBiotech Q1 2026 Earnings Results & Report $2.29 +0.09 (+4.09%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$2.28 0.00 (-0.22%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. XBiotech missed analyst earnings expectations in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$0.18 versus the $0.03 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 14, 2026TimeBefore Market Opens XBiotech EPS ResultsActual EPS-$0.18Consensus EPS $0.03Beat/MissMissed by -$0.21One Year Ago EPSN/AXBiotech Revenue ResultsActual RevenueN/AExpected Revenue$7.00 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile XBiotech Q1 2026 Earnings FAQ Did XBiotech beat earnings estimates for Q1 2026? XBiotech (NASDAQ:XBIT) reported earnings of -$0.18 per share for Q1 2026, missing the consensus estimate of $0.03. The report was announced on Thursday, May 14, 2026. XBiotech Earnings HeadlinesXBiotech (NASDAQ:XBIT) Share Price Breaks Below 50-Day Moving Average - Time to Sell?October 3, 2026 | americanbankingnews.comXBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial SpondyloarthritisJune 15, 2026 | globenewswire.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ RadarMay 14, 2026 | tipranks.comXBiotech: Q4 Earnings SnapshotMarch 13, 2026 | chron.comXBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?October 28, 2025 | msn.comSee More XBiotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like XBiotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XBiotech and other key companies, straight to your email. Email Address About XBiotechXBiotech (NASDAQ:XBIT), Inc. is a clinical-stage biotechnology company focused on developing therapies based on naturally occurring human antibodies. Its True Human antibody platform is designed to identify and produce antibody-based medicines that replicate immune proteins found in healthy individuals, with the goal of treating inflammatory, oncologic and other serious diseases. The company’s leading candidate has been bermekimab, a monoclonal antibody that targets interleukin-1 alpha, an inflammatory protein involved in multiple disease processes. XBiotech has evaluated bermekimab in clinical studies for conditions including cancer and inflammatory diseases. The company also develops additional antibody candidates and related technologies intended to support the discovery and manufacture of biologic medicines. Founded in 2005 and headquartered in Austin, Texas, XBiotech has conducted research and clinical development activities in the United States and internationally through clinical trials and collaborations. John Simard, the company’s founder, has served as its chief executive officer. XBiotech’s products remain in development, and the company does not have a broad portfolio of commercially marketed therapies.View XBiotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
